Ovid Therapeutics (OVID) Stock Statistics & Valuation Metrics

Ovid Therapeutics has a market cap or net worth of $379.80M. The enterprise value is $435.23M.

Ovid Therapeutics has 131,874,630 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ovid Therapeutics’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -29.46%.

The current PE Ratio of Ovid Therapeutics is ―. Ovid Therapeutics’s PEG ratio is 0.20.

In the last 12 months, Ovid Therapeutics had revenue of 7.25M and earned -17.41M in profits. Earnings per share was -0.24.

In the last 12 months, operating cash flow was -38.33M and capital expenditures 0.00, giving a free cash flow of -38.33M billion.

Ovid Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Ovid Therapeutics upcoming earnings date is May 13, 2026, TBA (Confirmed).

Ovid Therapeutics as a current ratio of 10.91, with Debt / Equity ratio of 10.27%

In the past 12 months, Ovid Therapeutics has paid 0.00 in taxes.

Ovid Therapeutics EV to EBITDA ratio is -2.86, with an EV/FCF ratio of -3.14.

Ovid Therapeutics has $69.64M in cash and marketable securities with $13.42M in debt, giving a net cash position of $56.22M billion.

Gross margin is 99.16%, with operating margin of -585.20%, and net profit margin of -240.13%.

The average price target for Ovid Therapeutics is $5.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy